Michael Barbella, Managing Editor01.29.21
North America's medtech deal activity slowed in the final quarter of last year.
The industry experienced a 17.3 percent decline in overall deal activity in the three months ending Dec. 31 compared to the same period in 2019, according to GlobalData’s deals database.
A total of 220 deals worth $16.93 billion were announced for the region during the fourth quarter of 2020, compared with 266 deals in Q4 2019.
Of all the deal types, venture financing saw most activity in Q4 2020 with 127, representing a 57.7 percent share for the region. Closely following venture financing was mergers and acquisitions with 70 deals, followed by private equity deals with 23 transactions, respectively capturing a 31.8 percent and 10.5 percent share of the overall deal activity for the quarter.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $11.94 billion, while private equity and venture financing deals totalled $2.69 billion and $2.31 billion, respectively.
The top five medical devices deals accounted for 55.03 percent of the overall value during Q4 2020.
The combined value of the top five medical devices deals stood at $9.32 billion, against the overall value of $16.93 billionn recorded for the quarter.
The top five medical devices industry deals of Q4 2020 tracked by GlobalData were:
The industry experienced a 17.3 percent decline in overall deal activity in the three months ending Dec. 31 compared to the same period in 2019, according to GlobalData’s deals database.
A total of 220 deals worth $16.93 billion were announced for the region during the fourth quarter of 2020, compared with 266 deals in Q4 2019.
Of all the deal types, venture financing saw most activity in Q4 2020 with 127, representing a 57.7 percent share for the region. Closely following venture financing was mergers and acquisitions with 70 deals, followed by private equity deals with 23 transactions, respectively capturing a 31.8 percent and 10.5 percent share of the overall deal activity for the quarter.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $11.94 billion, while private equity and venture financing deals totalled $2.69 billion and $2.31 billion, respectively.
The top five medical devices deals accounted for 55.03 percent of the overall value during Q4 2020.
The combined value of the top five medical devices deals stood at $9.32 billion, against the overall value of $16.93 billionn recorded for the quarter.
The top five medical devices industry deals of Q4 2020 tracked by GlobalData were:
- Koninklijke Philips’ $2.8 billion acquisition of BioTelemetry
- The $2.15 billion acquisition of Thrive Earlier Detection by Exact Sciences
- AdaptHealth’s $2 billion acquisition of AeroCare
- The $1.5 billion acquisition of Butterfly Network by Longview Acquisition
- Casdin Capital and Rock Springs Capital Management’s private equity deal with Exact Sciences for $869.2 millio.